Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5268345> ?p ?o }
Showing triples 1 to 29 of
29
with 100 triples per page.
- Q5268345 subject Q8412954.
- Q5268345 subject Q8852204.
- Q5268345 abstract "Dexpramipexole (KNS-760704) is a drug that was investigated by Knopp Biosciences and Biogen Idec for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS.In September 2009, dexpramipexole received Fast Track designation for ALS from the U.S. Food and Drug Administration (FDA). It has received Orphan Drug designation by both the FDA and the European Medicines Agency. Dexpramipexole is a low molecular weight, water-soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well tolerated in human subject testing.KNS-760704 is the enantiomer of pramipexole, and has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress. KNS-760704 was originally identified as a candidate therapy for ALS by James Bennett, M.D., Ph.D., then of the University of Virginia.A 2010 Phase II clinical trial involving 102 patients showed a slowing of ALS disease progression.In January 2013, Biogen Idec announced that it was discontinuing its development of dexpramipexole in ALS due to lack of efficacy in a Phase III study.".
- Q5268345 iupacName "(R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine".
- Q5268345 thumbnail Dexpramipexole.png?width=300.
- Q5268345 wikiPageExternalLink dexpramipexole-dihydrochloride.pdf.
- Q5268345 wikiPageWikiLink Q130146.
- Q5268345 wikiPageWikiLink Q1367466.
- Q5268345 wikiPageWikiLink Q204711.
- Q5268345 wikiPageWikiLink Q206901.
- Q5268345 wikiPageWikiLink Q213439.
- Q5268345 wikiPageWikiLink Q30612.
- Q5268345 wikiPageWikiLink Q323936.
- Q5268345 wikiPageWikiLink Q420060.
- Q5268345 wikiPageWikiLink Q421304.
- Q5268345 wikiPageWikiLink Q494483.
- Q5268345 wikiPageWikiLink Q5425270.
- Q5268345 wikiPageWikiLink Q8412954.
- Q5268345 wikiPageWikiLink Q864338.
- Q5268345 wikiPageWikiLink Q8852204.
- Q5268345 iupacname "-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine".
- Q5268345 type ChemicalCompound.
- Q5268345 type ChemicalSubstance.
- Q5268345 type ChemicalObject.
- Q5268345 type Thing.
- Q5268345 type Q11173.
- Q5268345 comment "Dexpramipexole (KNS-760704) is a drug that was investigated by Knopp Biosciences and Biogen Idec for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS.In September 2009, dexpramipexole received Fast Track designation for ALS from the U.S. Food and Drug Administration (FDA).".
- Q5268345 label "Dexpramipexole".
- Q5268345 depiction Dexpramipexole.png.